234 related articles for article (PubMed ID: 30583289)
1. Exosomal Release of L-Plastin by Breast Cancer Cells Facilitates Metastatic Bone Osteolysis.
Tiedemann K; Sadvakassova G; Mikolajewicz N; Juhas M; Sabirova Z; Tabariès S; Gettemans J; Siegel PM; Komarova SV
Transl Oncol; 2019 Mar; 12(3):462-474. PubMed ID: 30583289
[TBL] [Abstract][Full Text] [Related]
2. Peroxiredoxin 4: a novel secreted mediator of cancer induced osteoclastogenesis.
Rafiei S; Tiedemann K; Tabariès S; Siegel PM; Komarova SV
Cancer Lett; 2015 Jun; 361(2):262-70. PubMed ID: 25779674
[TBL] [Abstract][Full Text] [Related]
3. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
[TBL] [Abstract][Full Text] [Related]
4. Sinomenine inhibits osteolysis in breast cancer by reducing IL-8/CXCR1 and c-Fos/NFATc1 signaling.
Zhang Y; Zou B; Tan Y; Su J; Wang Y; Xu J; Tao L; Zhou H; Liu L; Li X
Pharmacol Res; 2019 Apr; 142():140-150. PubMed ID: 30797069
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of Bone Morphogenetic Proteins Type 1a Receptor (BMPR1a) in Breast Cancer Cells Protects Bone from Breast Cancer-Induced Osteolysis by Suppressing RANKL Expression.
Liu Y; Zhang RX; Yuan W; Chen HQ; Tian DD; Li H; Jiang X; Deng ZL; Wang Y
Cell Physiol Biochem; 2018; 45(5):1759-1771. PubMed ID: 29495003
[TBL] [Abstract][Full Text] [Related]
6. CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems.
Liverani C; Mercatali L; Spadazzi C; La Manna F; De Vita A; Riva N; Calpona S; Ricci M; Bongiovanni A; Gunelli E; Zanoni M; Fabbri F; Zoli W; Amadori D; Ibrahim T
Bone; 2014 Sep; 66():214-22. PubMed ID: 24956020
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E
J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200
[TBL] [Abstract][Full Text] [Related]
8. Reduced exosomal L-Plastin is responsible for radiation-induced bystander effect.
Freudenmann LK; Mayer C; Rodemann HP; Dittmann K
Exp Cell Res; 2019 Oct; 383(1):111498. PubMed ID: 31302031
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
Hussein O; Tiedemann K; Komarova SV
Bone; 2011 Feb; 48(2):202-11. PubMed ID: 20849994
[TBL] [Abstract][Full Text] [Related]
10. Human breast cancer induces osteoclast activation and increases the number of osteoclasts at sites of tumor osteolysis.
Clohisy DR; Palkert D; Ramnaraine ML; Pekurovsky I; Oursler MJ
J Orthop Res; 1996 May; 14(3):396-402. PubMed ID: 8676252
[TBL] [Abstract][Full Text] [Related]
11. Gentian violet inhibits MDA-MB-231 human breast cancer cell proliferation, and reverses the stimulation of osteoclastogenesis and suppression of osteoblast activity induced by cancer cells.
Yamaguchi M; Vikulina T; Weitzmann MN
Oncol Rep; 2015 Oct; 34(4):2156-62. PubMed ID: 26260090
[TBL] [Abstract][Full Text] [Related]
12. Quetiapine inhibits osteoclastogenesis and prevents human breast cancer-induced bone loss through suppression of the RANKL-mediated MAPK and NF-κB signaling pathways.
Wang H; Shen W; Hu X; Zhang Y; Zhuo Y; Li T; Mei F; Li X; Xiao L; Chu T
Breast Cancer Res Treat; 2015 Feb; 149(3):705-14. PubMed ID: 25667102
[TBL] [Abstract][Full Text] [Related]
13. Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis.
Logan JG; Sophocleous A; Marino S; Muir M; Brunton VG; Idris AI
J Bone Miner Res; 2013 May; 28(5):1229-42. PubMed ID: 23239200
[TBL] [Abstract][Full Text] [Related]
14. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis.
Park HR; Min SK; Cho HD; Kim DH; Shin HS; Park YE
J Korean Med Sci; 2003 Aug; 18(4):541-6. PubMed ID: 12923331
[TBL] [Abstract][Full Text] [Related]
15. Platycodin D Blocks Breast Cancer-Induced Bone Destruction by Inhibiting Osteoclastogenesis and the Growth of Breast Cancer Cells.
Lee SK; Park KK; Kim HJ; Kim KR; Kang EJ; Kim YL; Yoon H; Kim YS; Chung WY
Cell Physiol Biochem; 2015; 36(5):1809-20. PubMed ID: 26184636
[TBL] [Abstract][Full Text] [Related]
16. L-plastin Ser5 phosphorylation in breast cancer cells and in vitro is mediated by RSK downstream of the ERK/MAPK pathway.
Lommel MJ; Trairatphisan P; Gäbler K; Laurini C; Muller A; Kaoma T; Vallar L; Sauter T; Schaffner-Reckinger E
FASEB J; 2016 Mar; 30(3):1218-33. PubMed ID: 26631483
[TBL] [Abstract][Full Text] [Related]
17. RANKL-dependent and RANKL-independent mechanisms of macrophage-osteoclast differentiation in breast cancer.
Lau YS; Danks L; Sun SG; Fox S; Sabokbar A; Harris A; Athanasou NA
Breast Cancer Res Treat; 2007 Sep; 105(1):7-16. PubMed ID: 17151927
[TBL] [Abstract][Full Text] [Related]
18. 15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss.
Kim KR; Kim HJ; Lee SK; Ma GT; Park KK; Chung WY
PLoS One; 2015; 10(4):e0122764. PubMed ID: 25859665
[TBL] [Abstract][Full Text] [Related]
19. Involvement of cell-cell and cell-matrix interactions in bone destruction induced by metastatic MDA-MB-231 human breast cancer cells in nude mice.
Nakamura H; Hiraga T; Ninomiya T; Hosoya A; Fujisaki N; Yoneda T; Ozawa H
J Bone Miner Metab; 2008; 26(6):642-7. PubMed ID: 18979165
[TBL] [Abstract][Full Text] [Related]
20. Zerumbone abolishes RANKL-induced NF-kappaB activation, inhibits osteoclastogenesis, and suppresses human breast cancer-induced bone loss in athymic nude mice.
Sung B; Murakami A; Oyajobi BO; Aggarwal BB
Cancer Res; 2009 Feb; 69(4):1477-84. PubMed ID: 19190327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
